[Ip-health] Healing an ailing pharmaceutical system: prescription for reform for United States and Canada

Baker, Brook b.baker at northeastern.edu
Thu May 17 07:01:40 PDT 2018


https://www.bmj.com/content/bmj/361/bmj.k1039.full.pdf
Key messages
The US and Canadian pharmaceutical systems are dysfunctional
Costs are exorbitant, commercial goals distort drug development,
misleading promotion fosters misuse, and medications are too often
unaffordable for patients
We propose reforms that would provide universal drug coverage without
fees at the point of use while reducing prices through negotiations with
drug firms and, when needed, compulsory generic manufacture
Innovation would be enhanced through patent reform and by establishing
new public agencies to fund drug development and clinical trials
Drug safety, efficacy, and prescribing quality would be improved by raising
standards for approval and safety monitoring
While the proposals face formidable political obstacles, a popular mandate
exists for pharmaceutical reform in both nations


Professor Brook K. Baker
Northeastern U. School of Law
416 Huntington Ave.
Boston, MA 02115
Honorary Research Fellow, University of KwaZulu Natal
Health GAP (Global Access Project) Senior Policy Analyst
(w) 617-373-3217
(c) 617-259-0760
b.baker at northeastern.edu
Skype:  brook_baker







More information about the Ip-health mailing list